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Introduction
The management of systemic lupus erythematosus (SLE) is a challenging task. All interventions to-date are palliative
rather than curative as the pathogenesis of the disease remains enigmatic. Treatment-related side effects can be as
problematic as the disease itself. The following is a review of the practical management of the disease based on our
experience. (HK Pract 1996; 18: 475-480)
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To treat conservatively or
aggressively?
It is essential to decide the
strategy of therapy for each individual
SLE patient as once committed,
treatment has to be maintained for a
long period of time. In general, non-
life-threatening manifestations are
treated conservatively while life-
threatening major organ involvement
requires aggressive immuno-
suppressive therapy. Clinical subsets
(e.g. the antiphospholipid syndrome
in which immunosuppression is not
beneficial) have to be recognised.
(Table 1).
Table 1: Indications for conservative/aggressive treatment of systemic
lupus erythematosus (SLE)
Indications for conservative treatment of SLE
Musculoskeletal symptoms
Cutaneous lupus • '
Systemic upset ; >
Serositis :
Indications for aggressive treatment of SLE
Lupus nephritis
Cerebral lupus
Transverse myelitis
Peripheral neuropathy
Pneumonitis, pulmonary haemorrhage
Severe and refractory serositis
Severe haemolysis or thrombocytopenia
Myocarditis
(Continued on page 477)
' Address for correspondence: Dr C 5 Lau, Rheumatology Unit, University Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Pokfulam Road, Hong Kong.
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Conservative management
Musculoskeletal manifestations
Arthralgia, arthritis and myalgia are
common presenting symptoms of SLE.
They are usually mild but can
sometimes be very disabling. Non-
steroidal anti-inflammatory drugs
(NSAID) usually provide rapid relief
of symptoms. However, the use of
NSAID in SLE requires special
cautions. Through their inhibitory
effects on renal prostaglandins, all
NSAIDs (including sulindac) reduce
glomerular filtration rate and renal
blood flow, especially in patients
who have clinical and subclinical
nephritis, or are taking diuretics. Salt
and fluid retention may elevate blood
pressure and cause peripheral
oedema. Gastrointestinal toxicity with
bleeding can develop at any time
during therapy. Headache, dizziness,
and aseptic meningitis (particularly
with ibuprofen) may occur and
confuse with central nervous system
manifestation of the disease. Finally,
SLE patients are more prone to
NSAID-induced hepatotoxicity, which
is usually manifested as elevation of
liver transaminases. Therefore, it is
mandatory to monitor patients
closely for renal, gastrointestinal and
hepatic side-effects after commence-
ment of therapy.
When musculoskeletal symptoms
are not well controlled with NSAIDs,
a trial of antimalarials is indicated.
Hydroxychloroquine is preferred
because of its lower incidence of
retinal toxicity and other side-effects.
The start ing dose is 300 mg to
400mg/day and should be tapered
to a maintenance of 200mg/day
once a response is achieved
because retinal damage is related to
the cumulative dose. In unmonitored
patients, the incidence of
antimalarial retinopathy is 3-4%.1
Properly monitored, Spalton et al*
have shown that irreversible
retinopathy is unlikely to occur
when hydroxychloroquine, at a
daily recommended dose of less
than 6.5 mg/kg, in the absence of
renal dysfunction, is used for less than
10 years. Most rheumatologists
recommend referring patients to the
ophthalmologist for baseline eye
examination before the start of the
drug and regular follow up,
particularly when treatment has been
continued for more than 3 years. In
our Unit, a drug holiday, viz treatment
for 5 days per week, is introduced
when the patient has been stable on
hydroxychloroquine for 2 years. In
general, the drug is seldom used
continuously for longer than 5 years.
Besides retinopathy, other uncommon
side-effects of antimalarials include
corneal deposits, gastrointestinal
disturbance, rash, peripheral
neuropathy, proximal myopathy,
cardiomyopathy and skin
pigmentation.
For occasional patients whose
symptoms are resistant to
antimalarials, low dose prednisone
(less than 15mg/day) and even
immunosuppressives may be
considered if quality of life is
seriously impaired. These, however,
should be discontinued as soon as
the symptoms are controlled. It is
also noteworthy that local causes
such as avascular necrosis may give
rise to persistent pain in one or two
joints and should be seriously
excluded before more aggressive
treatment is considered.
Cutaneous lupus
Around 70% of all SLE patients
are photosensitive with f lares of
lupus activity. Patients should avoid
exposure to sunlight by wearing
protective clothings and applying
sunscreens. Acute lupus dermatitis
usually responds to topical steroids.
Fluorinated high.-potency prepara-
tions such as betamethasone and
fluocinonide are very effective but
are more likely to cause atrophy,
striae, acne and folliculitis. They
should not be used for more than 2
weeks (especially on face lesions),
after which less potent preparations
such as hydrocortisone should be
substituted.
Antimalarials are also useful in the
treatment of cutaneous lupus (acute,
subacute, chronic/discoid) because
of their sun-blocking, ant i -
inflammatory and immunosuppressive
effect. Sixty to 90% of patients have
excellent response to antimalarials.3
For hydroxychloroquine, improve-
ment often requires 3 to 6 months.
The dosage should be tapered once
when there is a response.
For patients who are resistant to
antimalarial therapy, more aggressive
treatment including systemic
glucocorticoids, dapsone, etretinate,
or cytotoxic drugs such as
azathioprine may be required. The
use of dapsone in cutaneous lupus
should be very cautious because of
its significant haematological
toxicities. We recently reported 2
cases of severe dapsone syndrome
after low dose treatment (50 mg/
day).4 One died as a result of
fulminant toxic hepatitis and
hypoalbuminaemia. The mechanism
of this syndrome is unclear and is
believed to be an extreme
idiosyncratic reaction to the drug.
Systemic complaints
Systemic upset such as fever,
fatigue and weight loss is common
and may be difficult to treat. NSAIDs,
salicylates, antimalarials and low dose
glucocorticoids are the main stay of
management although occasionally a
higher dose of steroid is required.
Serositis
Lupus serositis causes episodes of
chest and abdominal pain. They usually
respond to NSAIDs (especially
indomethacin), antimalarial or low
dose steroid (less than 15mg/day).
Significant effusion in the pericardial
or pleural cavities occurs infrequently
and requires drainage because it
compromises the function of the
heart and lung. More aggressive
immunosuppressive therapy may be
needed in refractory cases.
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Aggressive treatment of SLE
Patients with life-threatening
complications of SLE or involvement of
major orsan(s) should be assressively
treated. This usually besins with high
dose steroid, followed by cytotoxic
agents. Manifestations of SLE that
require high dose glucocorticoids are
listed in (Table 2). Some lupus
manifestations are not steroid
sensitive (e.g. pure membranous
glomerulonephritis, thrombosis) and
intense immunosuppression is not
justified. Infection may mimic disease
flare and should be vigorously
eliminated before the institution of
immunosuppression. When in doubt,
antibiotic coverage should be given
at the same time. Serological
evidence of increased disease
activity includes raised titre of anti-
DNA antibody and depressed serum
complement levels. In general, serum
C-reactive protein (CRP) level remains
normal or low except when there is
significant synovitis, serositis, active
vasculitis or coexisting infection.
Raised serum CRP should alert the
physician of infective complications.
Corticosteroids
Daily oral short-acting
glucocorticoids (prednisone,
prednisolone, methylprednisolone) is
the standard regimen for steroid
therapy in SLE. The starting dose for
prednisolone is usually between 0.5
to 1.5 mg/kg/day. In general, a higher
init ial dose may be required for
control of central nervous system
disease and severe renal and
haematological involvement. The
rapidity of response to steroid varies
among individuals and disease
manifestations. Organic brain
syndrome may improve within days
while cytopenia usually takes 5 - 1 5
days to recover. Serology markers
may only respond 1-3 weeks after
treatment. A complete response is
usually expected after 4 to 10 weeks.
If the desired effect is not obtained
within the appropriate time frame
despite a good compliance, a review
of the diagnosis, change of steroid
dose, additional cytotoxic therapy or
other modalities should be
considered.
Table 2 Manifestations of systemic lupus erythematosus (SLE) which are
responsive/resistant to steroid treatment
are usually : responsive to ;high'.close'..
Vasculitis •
Polyserositis
Myocarditis
Haemolysis, thrombocytopenia
Transverse;myelitis , , . ., \ /:,;.::, ; ;: . ;.
Peripheral neuropathy :: :
Manifestations of SLE which are often steroid-resistant
Thrombosis, antiphospholipid syhdrome... •. '
Pure membranous glomerulonephritis, scarred end-stage disease
'Mild behavioural/cognitive disturbances
Daily high-dose intravenous
methylprednisolone (15mg/kg) for 3
to 5 doses, followed by daily oral
prednisolone (40 - 60 mg) mainte-
nance, which is rapidly tapered, is
increasingly popular in the treatment
of SLE. Uncontrolled trials suggest
that more than 75% of patients with
severe nephritis, central nervous
system disease, pneumonitis,
polyserositis, vasculitis and throm-
bocytopenia improve within a few
days.5 The overall side effects are
probably not increased when
compared with the oral high-dose
regimen but acute psychosis, seizure,
rapid increase in blood pressure,
gastrointestinal bleeding, arrhythmia
and sudden death have been
reported.6
Cytotoxic agents
Azathioprine (a purine
antagonist) and cyclophosphamide
(an alkylating agent) are the two
commonest cytotoxic agents used in
the treatment of SLE. Both drugs
inhibit B-cells. Cyclophosphamide
has an additional suppressive effect
on the T-cells and is more effective,
but also more toxic. Previous studies
have shown that either of the drugs
together with corticosteroid is more
superior than corticosteroid alone in
the control of the disease in the long
run.7
Azathioprine
Azathioprine (1 -3 mgAg/day) is
used in lupus nephritis and as a
steroid sparing agent in many of the
less serious manifestations of the
disease. Although uncommon, an
idiosyncratic reaction causing marrow
aplasia or agranulocytosis may occur
during the first few weeks of therapy.
Adverse ef fects of chronic
azathioprine therapy include
increased rate of opportunistic
infection (especially herpes zoster),
marrow suppression (dose-related),
hepatic damage and malignancy.8
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Cydophosphamide
Cyclophosphamide is more toxic
than azathioprine and is reserved for
treatment of more severe and life-
threatening complications of SLE such
as proliferative/crescentic glomerulo-
nephritis, lupus cerebritis, severe
thrombocytopenia, pneumonitis and
pulmonary haemorrhage. Two
regimens are currently available.
Intravenous monthly pulse
cyclophosphamide (0.5 - 1 gm/m9
surface area) has the disadvantages
of the need for in-patient treatment,
venous access and a higher incidence
of nausea and vomiting. Daily oral
cyclophosphamide ( 1 - 2 mgAg/day)
is convenient and probably more
effect ive. However, the risk of
bladder toxicity such as haemorrhagic
cystitis is higher. We generally adopt
the oral regimen for our lupus
patients and it appears that Chinese
lupus patients tolerate this well and
there are extremely few cases of
cystitis noted.
Long term toxicities of
cyclophosphamide are significant
and it is generally agreed that the
drug should not be used for more
than 2 years. Opportunistic
infections may be life-threatening;
bone marrow suppression, increased
malignancies and infertility are of
major concern. Premature ovarian
failure contributes to osteoporosis
and accelerates atherosclerot ic
disease in women taking
corticosteroids. In our Unit,
cyclophosphamide treatment is
usually maintained for 6 months after
a remission is achieved. The
treatment is then switched to
maintenance azathioprine. This
sequential therapy regimen has been
shown to be useful for patients with
lupus nephritis.9
Monitoring of adverse effects during
immunosuppressive therapy
Osteoporosis, accelerated
atherosclerosis, avascular necrosis,
secondary diabetes, hypertension,
psychiatric disturbances, and
increased opportunistic infection are
well known long term side effects of
corticosteroids.10 It is therefore
important to reduce the steroid dose
once the disease is controlled. There
are many ways of doing this and the
alternate-day tapering regimen is most
popular as this is associated with
significantly less suppression of the
hypothalamic-pituitary axis, as well as
less nitrogen and potassium wasting,
hypertension, Cushingnoid changes
and infection.11
For patients taking long term
steroids, electrolytes, blood counts,
sugar level, blood pressure, intraocular
pressure and the lens should be
regularly checked and monitored.
Signs of infection and osteroporosis
should also be looked out for.
Patients should be advised to have
adequate calcium intake (1000 -
1500 mg/day) and Vitamin D can be
considered if 24 hour calcium
excretion is less than 120mg. Regular
complete blood counts and liver
function tests are mandatory in
patients taking cytotoxics.
Microscopic haematuria should be
screened for patients taking
cyclophosphamide. Finally, patients
should be warned of the possibility
of infert i l i ty and increased
malignancies before the start of
cyclophosphamide.
Special situations
Pregnancy
Patients with SLE should not be
deprived of the opportunity to
conceive. Exacerbation occurs in
around 50% of patients during
pregnancy and in the post-partum
period. The risk is higher when
disease is active within 6 months
before conception.12 Relapse of the
disease may lead to irreversible organ
damage while aggressive treatment
may lead to fetal death. It is therefore
important to give patients adequate
pre-pregnancy counselling and
contraceptive advice. In general,
pregnancy is only recommended
when the disease has been stable for
a comfortable period of time (e.g. 1 -
2 years) and should be closely
monitored, with the collaboration of
an experienced obstetrician. All
drugs used in SLE, with the exception
of corticosteroids, are potentially I
teratogenic/embryotoxic and should
be avoided, especially in the f irst
trimester of pregnancy.
Antiphospholipid syndrome (APS)
and recurrent abortion
APS is characterised by recurrent
vascular thrombosis, pregnancy
wastage, and thrombocytopenia
associated with a persistently positive
lupus anticoagulant or anti-cardiolipin
antibodies.13 It can exist alone as a
primary form or associated with SLE.
Daily low-dose aspirin or long-term
anticoagulation is the treatment of
choice. Immunosuppression is not
justified as the anti-cardiolipin
antibodies are notorious for its
steroid resistance. For those patients
who experience recurrent fetal loss,
low-dose aspirin, aspirin plus
prednisone, or subcutaneous heparin
treatment throughout the pregnancy
improves fetal survival.
Cytopenias
Severe cytopenia definitely
contributes to mortality in SLE. High
dose glucocorticoids (prednisone 1 -
1.5 mg/kg or intravenous pulse
therapy) is often needed. For severe
thrombocytopenia, intravenous
gammaglobulin (0.4gm/kg/day for 5
days or 1 gm/kg/day for 2 days) can
lead to a rapid increase in platelet
count and is reserved for emergency
treatment for life-threatening bleeding
or preparation for emergency surgery.
Cytotoxic agents including
azathioprine, cyclophosphamide and
vinca alkaloids may be tr ied in
steroid-resistant cases. Danazol, an
anabolic steroid, may be useful in
some cases of lupus
thrombocytopenia. However, it is less
effective in the younger patients and
the side effects of hirsutism,
menopausal symptoms, deepening of
voice, hepatitis and weight gain may not
be acceptable.
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Table 3 : Experimental therapies for systemic lupus erythematosus
Experimental therapies for SLE . . . / . . ; ' . . . /• ." ^ .^
Plasmapheresis, leukopheresis, cryophersis ^
Cyclosporin A . ^ . / . , .^ , / .
Intravenous immunbglobulins (IVIG) -
Manipulation of sex hormone levels (androgens, luteinizing hormone blocking
' :agents) ' ' - ; ' , ^  . ' : ; ; . ^ ' ' " ' : • • • " • . / • ; ' '
Newer immunosuppressives (FK506, rapamycin, mycophenolic acid)
Interventions of T-B cell interactions (monoclonal antibody against CD4, CD3, or
112 receptor, total lymphoid irradiation)
Drug-induced lupus
Many drugs are capable of
inducins a lupus-like syndrome,
characterised by fever, rash, arthritis,
serositis, a positive ANA and anti-
DNA-histone antibodies. Chlorpro-
mazine, hydralazine, procainamide,
isoniazid, a-methyl-dopa are
notorious for this. However, it should
not be confused with the many other
drugs which may exacerbate an
existins lupus. Sulphonamides,
anticonvulsants and oestrogen-
containing contraceptive pills have
been attributed to exacerbate lupus
activity from earlier studies and
should therefore be avoided in SLE
patients.
Pure membranous glomerulo-
nephritis
Lupus membranous glomerulo-
nephritis (WHO class V) is well known
for its resistance to steroid or
cytotoxic therapy, usins daily protein
excretion as a measure of response.
Renal failure occurs less frequently
and later than with proliferative
Slomerulonephritis. We usually treat
our patients with moderate to hish
dose steroid tosether with
azathioprine. If no response is
obtained after 6 - 1 2 weeks,
immunosuppression will be
gradually withdrawn, provided that
it is not due to other causes like renal
vein thrombosis and change of
histology into a more serious or
mixed form.
Experimental therapies
Table 3 lists the currently available
experimental therapies for SLE. It is
out of our scope here to mention all
of them in details. One drug that is
noteworthy, mentioned here, is
cyclosporin A (3 - 5 mg/kg/day)
which, when added to gluco-
corticoid therapy, has been shown to
improve renal and extrarenal
manifestations of SLE.14 Undesirable
effects include tremor, hirsutism,
hypertension, hyperlipidaemia and
nephrotoxicity. However, it is
expensive and should only be
considered in patients with steroid-
resistant disease or marrow
suppression when cytotoxic agents
cannot be use.
Conclusion
SLE is a complex disease with
diverse manifestations and wide
individual variability in the
presentation and severity. The goal
of management is not just to induce
remission in the short term, but also
to minimise toxicities of long term
therapy. Expert care from
experienced rheumatologists is
needed. The use of various drugs like
antimalarials, corticosteroids and
cytotoxic agents should be fully
justified and carefully monitored. •
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